Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:18:10.125Z.
Consensus retrieved: 2026-10-06T15:24:48.327Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:18:10.125Z.
Quote observation: 2026-10-06T19:15:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dfe3b7eb0a07bb41d8210bce1124860262d7a4d6e18a93ea2ad6da4bd4c55c28
Forward PE Ratio (N/A) = Dated Quote Price ($276.50) / Consensus Forward EPS ($-13.60)
FORWARD PE RATIO
N/A
Praxis Precision Medicines, Inc.
Market Cap
$7.71B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Praxis Precision Medicines, Inc. (PRAX) | $7.71B | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $7.78B | 237.09 |
| HealthEquity, Inc. (HQY)vs › | $7.62B | 19.29 |
| Cytokinetics, Incorporated (CYTK)vs › | $7.60B | N/A |
| Hinge Health, Inc. (HNGE)vs › | $7.57B | 42.17 |
| TG Therapeutics, Inc. (TGTX)vs › | $8.00B | 53.67 |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.31B | N/A |
| Alkermes plc (ALKS)vs › | $6.99B | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.43B | 17.04 |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.67B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $276.50, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-13.60 | $-15.16 – $-12.39 | 14 | n/m |
| 2027-12-31 | $-9.95 | $-14.21 – $-3.72 | 13 | n/m |
| 2028-12-31 | $5.71 | $-7.96 – $32.24 | 16 | 48.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
